Clinical Guides
Bronchiectasis
A clinically focused adult bronchiectasis guide covering CT confirmation, treatable causes, tuberculosis and NTM safeguards, airway clearance, culture-led exacerbation care, antimicrobial limits, haemoptysis and India-specific referral pathways.
MedNext Academy | 13 min read
Bronchiectasis
A clinically focused adult bronchiectasis guide covering CT confirmation, treatable causes, tuberculosis and NTM safeguards, airway clearance, culture-led exacerbation care, antimicrobial limits, haemoptysis and India-specific referral pathways.
Summary
Bronchiectasis is a clinical-radiological syndrome in which permanently dilated bronchi are associated with chronic or recurrent airway infection, inflammation and impaired mucus clearance. A computed-tomography appearance alone is not enough: mild or traction bronchial dilatation can accompany ageing or fibrotic lung disease without the typical syndrome. Conversely, a patient with daily purulent sputum, recurrent chest infections or unexplained haemoptysis should not be managed indefinitely as asthma or ordinary bronchitis without appropriate imaging and microbiology.
Thin-section chest CT confirms the anatomical diagnosis when the patient is clinically stable. Assessment then asks why it developed, how severe it is, which organisms are present and what is modifiable. Important causes or associations include previous tuberculosis or severe pneumonia, non-tuberculous mycobacteria, allergic bronchopulmonary aspergillosis, immunodeficiency, aspiration, primary ciliary dyskinesia, autoimmune disease and selected congenital disorders. In India, active tuberculosis must be distinguished from post-tuberculosis structural damage before immunosuppression or prolonged antibiotics.
Management is a cycle: teach individualized airway-clearance techniques, support exercise and vaccination, treat the underlying cause, obtain sputum cultures, recognize exacerbations early and use antimicrobials selectively. Long-term macrolide or inhaled antibiotic therapy is specialist treatment because benefit is concentrated in selected patients and resistance, cardiac, hearing, liver, fungal and mycobacterial harms matter. Major haemoptysis, sepsis or respiratory failure is an emergency. This draft remains educational and quarantined following MedNext Clinical Team review.
How Common Is It?
Measured prevalence varies substantially because CT access, diagnostic coding, age distribution and the threshold for labelling radiological dilatation differ. Bronchiectasis becomes more common with age and is increasingly recognized when CT is performed for recurrent infection, haemoptysis or chronic sputum. A prevalence estimate from a European database cannot be applied directly to India, where tuberculosis, post-infectious disease, environmental exposures and access to respiratory specialists alter the population being detected.
Clinical burden is uneven. Some people have localized stable disease with infrequent infections; others experience daily sputum, repeated antibiotic courses, chronic Pseudomonas aeruginosa infection, declining lung function, undernutrition, anxiety, haemoptysis and hospital admission. Exacerbation frequency, symptoms, microbiology, radiological extent, lung function and comorbidity are more useful for care than a single national percentage. Record the patient's usual sputum volume and colour, exercise tolerance and annual exacerbation pattern so that future change can be recognized.
Underdiagnosis and overdiagnosis are both possible. Limited CT access can leave recurrent productive cough labelled as repeated pneumonia, while incidental traction bronchiectasis on a scan can lead to unnecessary antibiotics. Chronic cough in India also requires consideration of active tuberculosis, asthma, COPD, reflux, upper-airway disease and malignancy. A high-quality service therefore confirms the syndrome, searches for an underlying cause and follows outcomes rather than treating every dilated airway or every cough as the same disease.
Risk Factors
Previous pulmonary infection is a major clue. Ask about treated or incompletely treated tuberculosis, severe bacterial pneumonia, measles or pertussis in childhood, recurrent infections and prior lung abscess. In a patient with old TB, new constitutional symptoms or radiological change may represent reactivation, another infection or malignancy rather than a simple bronchiectasis flare. Non-tuberculous mycobacteria can be a cause, complication or colonizing isolate; diagnosis requires clinical, radiological and microbiological synthesis rather than one positive culture.
Immune and inflammatory associations include hypogammaglobulinaemia, common variable immune deficiency, HIV, haematological malignancy, transplant-related immunosuppression, rheumatoid arthritis, inflammatory bowel disease and allergic bronchopulmonary aspergillosis. Asthma with recurrent fleeting opacities, high total IgE, Aspergillus sensitisation and central bronchiectasis raises ABPA. Childhood-onset disease, chronic sinusitis, otitis, infertility or organ laterality abnormalities suggests primary ciliary dyskinesia. Cystic fibrosis is less common in Indian adults but should be considered when phenotype or ancestry supports it.
Aspiration risk arises from dysphagia, neurological disease, impaired consciousness and oesophageal or reflux disorders, but reflux testing or treatment should follow symptoms and clinical suspicion. Localized obstruction can reflect a foreign body, broncholith, tumour or stenosis and may require bronchoscopy. Smoking, biomass exposure and occupational dust can coexist with COPD or other lung injury without being a complete causal explanation. Risk assessment is not a checklist for indiscriminate testing; it identifies treatable conditions, infection-control needs and family implications.
Diagnosis
History
Ask about chronic daily cough, sputum amount, colour, odour and ease of clearance; recurrent chest infections; antibiotic response; breathlessness; wheeze; fatigue; pleuritic pain; fever; weight loss and haemoptysis. Establish childhood disease, pneumonia, tuberculosis exposure and treatment, sinus or ear disease, infertility, aspiration symptoms, autoimmune disease, asthma, atopy, immunosuppression and family history. Document stable baseline, exacerbations and hospital admissions over the previous year, prior organisms and antimicrobial courses.
Examination
Record respiratory rate, saturation, temperature, weight and body-mass trajectory. Crackles, wheeze and digital clubbing may occur but none confirms the diagnosis. Look for cyanosis, increased work of breathing, focal findings, cor pulmonale, cachexia, sinus disease, joint or skin features and signs of immune or systemic illness. During haemoptysis, assess airway, circulation and bleeding severity before a detailed routine examination. Functional status and exercise desaturation can reveal severity not evident at rest.
Investigations
Perform thin-section CT to confirm bronchiectasis, ideally in clinical stability, and review distribution, mucus plugging, air trapping, nodules, cavities and an obstructing lesion. Obtain sputum for routine bacterial culture when stable and during exacerbations; mycobacterial cultures are required where indicated and before long-term macrolides. Baseline evaluation commonly includes full blood count, total IgE, Aspergillus sensitisation testing and serum immunoglobulins. Spirometry describes impairment but does not confirm bronchiectasis. Additional tests for CF, ciliary dysfunction, aspiration, autoimmunity, HIV or bronchoscopy are phenotype-driven. Investigate suspected active TB through current molecular and microbiological pathways.
Differential Diagnosis
Chronic productive cough can result from COPD, asthma with mucus hypersecretion, chronic bronchitis, active tuberculosis, non-tuberculous mycobacterial disease, lung abscess, malignancy, aspiration, cystic fibrosis or chronic infection behind an obstruction. Upper-airway cough syndrome and reflux may coexist but usually do not explain recurrent focal consolidation, large purulent sputum volumes or characteristic CT changes. A normal chest radiograph does not exclude bronchiectasis, while CT airway dilatation must be matched to symptoms.
Traction bronchiectasis occurs when fibrotic lung pulls bronchi open. The dominant problem may be interstitial lung disease rather than chronic airway sepsis, and management differs. ABPA may produce central bronchiectasis, mucus impaction and variable opacities in a patient with asthma, but requires immunological evidence and clinical context. Active TB is suggested by constitutional symptoms, exposure, new cavitation or nodular change and microbiological evidence; old scars cannot prove that new symptoms are post-TB.
NTM pulmonary disease requires compatible symptoms, imaging and repeated or appropriately obtained microbiology; a single sputum isolate should not trigger prolonged multidrug treatment. Localized disease raises foreign body, endobronchial tumour or post-obstructive damage. Recurrent haemoptysis can also arise from TB, cancer, pulmonary embolism, aspergilloma, vascular malformation or mitral disease. During an apparent exacerbation, reconsider pneumonia, heart failure, PE and pneumothorax when severity, pain, physiology or radiology is atypical. Diagnostic discipline prevents both missed infection and unnecessary antibiotic escalation.
Management
Every patient should receive an airway-clearance assessment from a respiratory physiotherapist or appropriately trained clinician. Techniques are selected for symptoms, imaging, reflux, haemoptysis, cognition, preference and available devices, then reviewed for actual effectiveness. Active cycle breathing or an oscillating positive-expiratory-pressure method may be used; positioning is adapted when head-down drainage worsens reflux or breathlessness. Exercise and pulmonary rehabilitation improve capacity in suitable patients, while hydration and selected mucoactive approaches may help difficult sputum. Routine cough suppression is usually counterproductive.
Treat the cause where possible: immune replacement for proven antibody deficiency, specialist ABPA treatment, aspiration management, removal of obstruction, and TB or NTM therapy only through the relevant confirmed pathway. Vaccination, nutrition, smoking cessation and management of asthma, COPD, sinus disease and reflux reduce modifiable risk. Inhaled corticosteroids are not routine bronchiectasis therapy unless another indication such as asthma or selected COPD exists. Bronchodilators are individualized by airflow obstruction, symptoms and response.
An exacerbation is a sustained deterioration from baseline, commonly involving cough, sputum volume, viscosity or purulence, with possible breathlessness, wheeze, haemoptysis, fever or pleurisy. Send sputum before antibiotics when feasible, but do not delay treatment in a seriously ill patient. Select therapy using severity, prior organisms and susceptibility, then review response and culture. Recurrent exacerbations despite optimized clearance require specialist review before long-term antibiotics. Surgery is uncommon and reserved for carefully selected localized disease or complications after multidisciplinary assessment.
Prescribing Information
Antibiotic choice for an exacerbation is guided by the most recent reliable sputum culture, current sample, prior resistance, allergy, renal and hepatic function, pregnancy, illness severity and local formulary. Oral treatment is preferred when the patient is stable and can absorb medicines; intravenous therapy and hospital care are considered for severe illness, resistant organisms, treatment failure or inability to take oral drugs. Current guidelines describes a seven-to-fourteen-day range, while BTS commonly uses fourteen days, especially for Pseudomonas; duration must be individualized and reviewed rather than copied automatically.
Do not repeatedly prescribe the same empirical antibiotic without obtaining microbiology and asking whether the episode is truly an exacerbation. Fluoroquinolones carry important disabling and potentially prolonged adverse-effect warnings and should be reserved for situations where guideline and susceptibility reasoning support them. Aminoglycoside exposure requires renal, auditory and interaction safeguards. Document organism, susceptibility, indication, planned duration, response and adverse effects so that the next prescriber has an antimicrobial history.
Long-term macrolides are for adults at high exacerbation risk after optimized care; long-term inhaled antibiotics are specifically supported for chronic Pseudomonas aeruginosa infection at high exacerbation risk. Before low-dose macrolide monotherapy, assess NTM history and obtain sputum for mycobacteria if NTM disease is clinically possible; recognized pathogenic NTM precludes this monotherapy. Review QT risk and QT-prolonging medicines, obtain an ECG and liver tests before treatment, repeat the ECG at one month and with a new QT-risk medicine or dose increase, and repeat liver tests at one month then six-monthly. Counsel and monitor for hearing or balance symptoms and antimicrobial resistance. Inhaled corticosteroids and oral steroids are not routine unless a separate indication exists. A self-management or rescue plan must specify who qualifies, which sample to send and when review is mandatory; it is not permission for uncontrolled repeated courses.
When to Refer
Refer to respiratory medicine when CT confirms bronchiectasis, the diagnosis is uncertain, an underlying cause needs specialist testing, or symptoms and exacerbations remain significant. Early referral is particularly important with chronic Pseudomonas or MRSA, possible NTM, ABPA, immunodeficiency, primary ciliary dyskinesia, cystic fibrosis phenotype, localized obstruction, rapid lung-function decline, recurrent hospital admission, oxygen need or consideration of long-term antibiotics. Children and adolescents require paediatric pathways because causes and management are not identical to adult disease.
Hospital assessment is required for sepsis, respiratory failure, haemodynamic instability, new confusion, inability to maintain oral intake, significant hypoxaemia, rapidly worsening symptoms, treatment failure with resistant organisms or a complication such as pneumonia. Major or ongoing haemoptysis needs emergency transfer to a centre able to protect the airway, resuscitate, image bronchial circulation and provide bronchial-artery embolisation or surgical support. Do not send a bleeding patient unmonitored in private transport.
A useful referral includes CT images and report, stable and exacerbation cultures including mycobacterial results, spirometry, exacerbation and antibiotic history, haemoptysis details, baseline saturation, immunoglobulins, IgE and Aspergillus testing, suspected cause, comorbidities and current clearance method. In India, choose a medical-college or specialist centre with the capability actually required. Suspected active TB follows the NTEP-linked diagnostic and notification pathway alongside appropriate infection-control measures rather than a routine bronchiectasis appointment alone.
Red Flags
Major haemoptysis is defined clinically by threat to airway, gas exchange or circulation rather than a universally safe volume threshold. Rapid bleeding, inability to clear blood, hypoxaemia, tachypnoea, hypotension, falling haemoglobin or reduced consciousness demands emergency action. Position and airway strategy depend on known bleeding side and expertise; early respiratory, critical-care, interventional-radiology and thoracic input may be needed. Small recurrent haemoptysis still warrants assessment for infection, TB, NTM, aspergilloma, cancer and vascular sources.
Other red flags include a silent or exhausted patient, rising carbon dioxide, severe hypoxaemia, new confusion, cyanosis, sepsis, pleuritic pain with instability, rapidly worsening focal radiology or failure to improve on an appropriately selected antibiotic. New weight loss, persistent fever, night sweats, lymphadenopathy, cavitation or increasing haemoptysis requires renewed TB and malignancy evaluation rather than attribution to the known structural disease.
Drug-related warnings include syncope or palpitations with QT-prolonging therapy, new hearing or balance disturbance, jaundice, severe diarrhoea, tendon or neurological symptoms after a fluoroquinolone, renal injury with nephrotoxic agents and allergic reactions. Before long-term macrolide therapy, an unrecognized NTM infection is a safety red flag because monotherapy can select resistance. Patients need explicit instructions for increasing breathlessness, chest pain, fever, confusion, reduced urine, inability to clear secretions or more than streak haemoptysis, with a named emergency route.
Indian Clinical Context
Post-tuberculosis lung disease is a particularly important bronchiectasis context in India, but a remote TB history must not become a blanket explanation. New or worsening cough, fever, weight loss, haemoptysis or radiological change requires assessment for active TB using current WHO- and NTEP-aligned molecular and microbiological tests. Collect sputum safely, use appropriate airborne-infection precautions and follow notification requirements. NTM should also be considered when symptoms and nodular, cavitary or tree-in-bud imaging persist despite ordinary antibacterial treatment.
Access to thin-section CT, fungal immunology, quantitative immunoglobulins, specialist physiotherapy, home intravenous therapy, inhaled antibiotics and embolisation varies widely. A safe district-level plan may focus on confirmation, sputum collection, taught clearance, targeted antibiotics and a defined escalation link, while tertiary centres investigate rare causes and advanced treatment. Do not advertise a long-term antibiotic strategy that cannot be monitored for ECG, liver, hearing, resistance and mycobacterial safety.
Cost and travel affect adherence. Combine investigations where possible, provide written clearance instructions in the patient's language, record the latest culture where primary and hospital clinicians can retrieve it, and choose affordable devices or manual techniques that the patient can sustain. Biomass exposure, smoking, undernutrition and coexisting diabetes or COPD should be addressed without stigma. International BTS, ERS and international guidelines recommendations inform care but are not Indian national formularies; local susceptibility data, NTEP requirements and the capacity of the receiving service remain decisive.
NMC Competency Mapping
Bronchiectasis integrates NMC CBME learning across respiratory medicine, microbiology, radiology, pharmacology, community medicine and AETCOM. At Know level, the learner should explain the infection-inflammation-mucus-clearance cycle, recognize post-infectious and immune causes, identify common organisms and distinguish clinical bronchiectasis from incidental traction change. At Know How level, the learner should select thin-section CT for confirmation, interpret the distribution, construct a cause-directed test set and use stable and exacerbation sputum cultures to guide management.
At Show How level, a learner can present a structured sputum and exacerbation history, demonstrate or teach a simple airway-clearance method under appropriate supervision, interpret a culture and susceptibility report, and safety-net haemoptysis. Cases should require distinction between active TB, post-TB damage, NTM and routine bacterial exacerbation, with infection-control action where appropriate. Learners should explain why macrolide monotherapy is unsafe when NTM disease has not been excluded.
At Perform level, clinical tasks remain within supervised scope and local competence. This guide does not certify independent bronchoscopy, non-invasive ventilation, embolisation, advanced physiotherapy prescription or long-term antimicrobial initiation. AETCOM outcomes include negotiating a feasible clearance plan, discussing chronic sputum without stigma, supporting antimicrobial stewardship, explaining uncertain evidence and coordinating referrals across settings. Assessment should reward longitudinal care and documentation rather than a memorized antibiotic list.
Key Exam Pearls for NEET PG
The classic CT feature is bronchial dilatation relative to the accompanying pulmonary artery, with failure of normal tapering and visibility of bronchi near the pleura; interpret these findings with symptoms. High-resolution or thin-section CT confirms diagnosis. Common clinical clues are chronic productive cough, recurrent infection, coarse crackles, haemoptysis and clubbing, but any may be absent. Localized disease suggests obstruction or prior focal infection; diffuse disease broadens the search to immune, ciliary, aspiration, allergic and systemic causes.
An adult work-up commonly includes sputum culture, mycobacterial culture, full blood count, serum immunoglobulins, total IgE and Aspergillus sensitisation testing. ABPA is associated with asthma, immunological evidence and often central bronchiectasis. Active TB and NTM require microbiological confirmation pathways; one NTM isolate does not equal disease. Airway clearance is foundational. Inhaled corticosteroids are not routine without asthma or another indication.
Exacerbation antibiotics are informed by previous and current sputum susceptibility, severity and response. Pseudomonas infection predicts greater complexity and may alter eradication or long-term strategies. Long-term macrolides can reduce exacerbations in selected frequent exacerbators but require NTM exclusion and cardiac, liver, hearing and resistance safeguards. Major haemoptysis is an airway emergency; bronchial arteries are the usual source and embolisation is often the definitive non-surgical intervention. A strong exam answer links CT confirmation, cause search, microbiology, airway clearance and escalation rather than listing antibiotics alone.
Frequently Asked Questions
Does a CT report of bronchiectasis always mean clinical bronchiectasis?
No. The radiological finding must be matched to chronic or recurrent airway symptoms and the wider lung pattern. Traction bronchiectasis can accompany fibrosis without a dominant suppurative airway syndrome, and mild dilatation may be incidental. A clinician should review CT quality, distribution, mucus plugging and associated features, then decide whether cause investigation and bronchiectasis management are appropriate.
Why are sputum cultures needed when symptoms worsen?
Previous organisms help choose initial therapy, but pathogens and resistance can change. A fresh sample taken before antibiotics when feasible allows bacterial culture and susceptibility review; mycobacterial testing is ordered when clinically indicated. Treatment should not be delayed in a seriously ill patient. Results are interpreted with clinical response, because an isolate may represent chronic infection or colonisation rather than the sole cause of deterioration.
Can everyone with recurrent bronchiectasis exacerbations take a long-term macrolide?
No. Long-term antibiotics are considered only after confirming true exacerbations, optimizing airway clearance and treating contributing disease. A specialist assesses likely benefit against resistance, QT prolongation, interactions, liver injury and hearing or balance effects. Active NTM infection must be excluded appropriately before macrolide monotherapy, because resistance can compromise future multidrug treatment.
When is haemoptysis in bronchiectasis an emergency?
It is an emergency when bleeding threatens airway clearance, oxygenation or circulation, is rapid or ongoing, or accompanies hypoxaemia, hypotension, confusion or substantial haemoglobin loss. Volume estimates are often unreliable. Arrange monitored transfer to a capable centre. Even small recurrent bleeding needs timely evaluation for infection, tuberculosis, NTM, aspergilloma, malignancy and other vascular or pulmonary causes.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic